DMIIR
NASDAQ
$0.08
Drugs Made In America Acquisition II Corp Right (DMIIR)
Drugs Made In America Acquisition II Corp. Right (DMIIR) is a special purpose acquisition company (SPAC) strategically focused on merging with innovative pharmaceutical firms dedicated to bolstering domestic drug manufacturing capabilities. Led by an experienced management team, DMIIR is positioned to address the growing demand for affordable and accessible medications within the U.S. healthcare landscape. The company seeks to execute targeted acquisitions that not only enhance shareholder value but also contribute to the strengthening of the essential healthcare infrastructure in America, ultimately fostering a more resilient and self-sufficient pharmaceutical ecosystem.
This company is also listed under the following tickers: DMII, DMIIU.
Market Cap
$1.11M
P/E Ratio
0.28
Free Cash Flow Yield
-87.50%
Beta (5Y)
0.13
Price Chart
Valuation
Market Cap$1.11M
P/E0.28
Profitability
Gross Profit (TTM)-$812K
EBITDA$8.58M
EPS$0.29
Financial Health
Debt-to-Equity-2.5%
Free Cash Flow Yield-87.50%
Growth & Risk
Beta (5Y)0.13
Sharpe Ratio-0.39